<DOC>
	<DOCNO>NCT01486329</DOCNO>
	<brief_summary>First-in-human phase I dose escalation study patient locally advance , inoperable stage IV pancreatic cancer examine safety , tolerability , immune response investigational VEGFR-2 DNA vaccine VXM01 examine safety tolerability , clinical immunogenic response investigational vascular endothelial growth factor receptor 2 ( VEGFR-2 ) DNA vaccine VXM01 , define maximum tolerate dose .</brief_summary>
	<brief_title>VXM01 Phase I Dose Escalation Study Patients With Locally Advanced , Inoperable Stage IV Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Written inform consent , sign date Locally advance , inoperable stage IV pancreatic cancer patient accord UICC base diagnostic image use computertomography ( CT ) histological examination Male postmenopausal female Age equal 18 year Chemotherapy naïve within 60 day screen visit except gemcitabine treatment Karnovsky index &gt; 70 Life expectancy &gt; 3 month Adequate renal , hepatic , bone marrow function Absolute neutrophil count &gt; 1500/µL Hemoglobin &gt; 10 g/dL Platelets &gt; 75000/µL Prothrombin time international normalize ratio ( INR ) &lt; 1.5 time upper limit normal ( ULN ) ( except anticoagulant treatment ) Aspartate aminotransferase &lt; 4 time ULN Alanine aminotransferase &lt; 4 time ULN Total bilirubin &lt; 3 time ULN Creatinine clearance estimate accord CockcroftGault &gt; 30 mL/min Proteinuria &lt; 1 g protein 24 h urine collection State pancreas resection ( complete partial ) Resectable disease Drug trial participation within 60 day screen visit Other previous current malignancy except basal squamous cell skin cancer , situ cervical cancer , cancer patient diseasefree &lt; 2 year Prior vaccination Ty21a Cardiovascular disease define : Uncontrolled hypertension ( systolic blood pressure &gt; 160 mmHg diastolic blood pressure &gt; 100 mmHg ) Arterial thromboembolic event within 6 month randomization include : Myocardial infarction Unstable angina pectoris Cerebrovascular accident Transient ischemic attack Congestive heart failure New York Heart Association grade III IV Serious ventricular arrhythmia require medication Clinically significant peripheral artery disease &gt; grade 2b accord Fontaine Hemoptysis within 6 month randomization Esophageal varix Upper low gastrointestinal bleeding within 6 month randomization Significant traumatic injury within 4 week randomization Nonhealing wound , bone fracture history gastrointestinal ulcer within three year inclusion , positive gastroscopy within 3 month inclusion Gastrointestinal fistula Thrombolysis therapy within 4 week randomization Bowel obstruction within last 30 day screen visit Liver cirrhosis ≥ grade B accord ChildPugh ScoreClassification Presence acute chronic systemic infection Radiotherapy within 4 week randomization Major surgical procedure , open biopsy within 4 week randomization Fine needle aspiration within 7 day randomization Chronic concurrent therapy within 2 week doubleblind study period : Corticosteroids ( except steroid adrenal failure ) immunosuppressive agent Antibiotics Bevacizumab Any epidermal growth factor receptor inhibitor Chemotherapy except gemcitabine Day 10 Multidrug resistant gramnegative germ Pregnancy Lactation Inability comply study and/or followup procedure History disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug might affect interpretation study result render patient high risk treatment complication Women childbearing potential Any history drug hypersensitivity Any condition result undue risk patient study participation accord investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Pancreatic cancer</keyword>
	<keyword>Cancer vaccine</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Inoperable</keyword>
	<keyword>Gemcitabine chemotherapy</keyword>
	<keyword>Locally advanced</keyword>
</DOC>